CDK4 and cancer: On the other hand, abemaciclib and palbociclib showed similar activity (albeit with different potency) in a large panel of cancer cell lines [6], and all three CDK4/6 inhibitors exhibit greatest effect in the presence of functional RB [5, 6, 47–49].